INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 136 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $14,000 | – | 778 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |